Scalper1 News
Shares of biotech startup Agios Pharmaceuticals (AGIO) soared 20% in the stock market today to a new high above 64 after it said it would report data from a key clinical trial earlier than expected, leading analysts to believe the news will be good. Agios said it will provide the first data from an ongoing phase one study of AG-120, a product it’s developing as a treatment for blood cancer, on Nov. 19 at a symposium in Barcelona. The trial started Scalper1 News
Scalper1 News